{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T03:34:49Z","timestamp":1793676889435,"version":"4.5.1"},"reference-count":83,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T00:00:00Z","timestamp":1769472000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T00:00:00Z","timestamp":1769472000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100011541","name":"U.S. Department of Health & Human Services | NIH | NCI | Division of Cancer Epidemiology and Genetics, National Cancer Institute","doi-asserted-by":"publisher","award":["P30 CA91842"],"award-info":[{"award-number":["P30 CA91842"]}],"id":[{"id":"10.13039\/100011541","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001006","name":"Breast Cancer Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001006","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    CDK4\/6 inhibitors (CDK4\/6i) improve outcomes for estrogen receptor (ER) positive\/HER2-negative breast cancers (BCs), yet intrinsic and acquired resistance exist. Here, we evaluated anastrozole in combination with palbociclib (ANA\/PAL) in the NeoPalAna Endocrine-Resistant cohort (NCT01723774). Thirty-four patients with clinical stage II\/III ER\u2009+\u2009\/HER2\u2013 BCs resistant to standard neoadjuvant endocrine therapy (on-treatment Ki67\u2009&gt;\u200910%) received neoadjuvant ANA\/PAL, with serial biopsies analyzed. The primary endpoint, complete cell cycle arrest (CCCA; Ki67\n                    <jats:sub>C1D15<\/jats:sub>\n                    \u2009\u2264\u20092.7% at cycle 1, day 15), was achieved in 57.6% of patients (95%CI: 39.2\u201374.5%). Resistance to ANA\/PAL (Ki67\n                    <jats:sub>C1D15<\/jats:sub>\n                    \u2009&gt;\u200910%) was associated with higher pre-treatment tumor grade, Ki67, and specific PAM50 subtypes. Resistant tumors demonstrated reduced ER signaling and upregulation of cell cycle, mTOR, interferon, JAK\/STAT, and immune checkpoints. Additionally, a 33-gene signature that predicted neoadjuvant Ki67 response to ANA\/PAL was prognostic in a metastatic validation cohort. These findings underscore dysregulated oncogenic pathways as potential resistance mechanisms and biomarkers of response to CDK4\/6i.\n                  <\/jats:p>","DOI":"10.1038\/s41467-026-68570-6","type":"journal-article","created":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T10:02:27Z","timestamp":1769508147000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Biomarkers of response to neoadjuvant palbociclib plus anastrozole in endocrine-resistant estrogen receptor-positive\/HER2-negative breast cancer: a phase 2 trial"],"prefix":"10.1038","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3240-8989","authenticated-orcid":false,"given":"Tim","family":"Kong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1635-8800","authenticated-orcid":false,"given":"Alex","family":"Mabry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maureen","family":"Highkin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony Z.","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeremy","family":"Hoog","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhanfang","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrian","family":"Gonzales-Gonzales","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shana","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-9496-6270","authenticated-orcid":false,"given":"Yingduo","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2454-7441","authenticated-orcid":false,"given":"Mateusz","family":"Opyrchal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lindsay","family":"Peterson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6766-2258","authenticated-orcid":false,"given":"Foluso","family":"Ademuyiwa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Margenthaler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Aft","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine","family":"Glover-Collins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leslie","family":"Nehring","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Tao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Souzan","family":"Sanati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3855-9745","authenticated-orcid":false,"given":"Ian S.","family":"Hagemann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fouad","family":"Boulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Holt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1517-2975","authenticated-orcid":false,"given":"Li","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9113-5020","authenticated-orcid":false,"given":"Wenge","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8564-5400","authenticated-orcid":false,"given":"Stephen T.","family":"Oh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0998-4996","authenticated-orcid":false,"given":"Jianxin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agnieszka K.","family":"Witkiewicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5130-5969","authenticated-orcid":false,"given":"Erik S.","family":"Knudsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1977-8894","authenticated-orcid":false,"given":"Ron","family":"Bose","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1069-6983","authenticated-orcid":false,"given":"Jason D.","family":"Weber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Goetz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donald","family":"Northfelt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2759-3072","authenticated-orcid":false,"given":"Jingqin","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8156-7492","authenticated-orcid":false,"given":"Cynthia X.","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,27]]},"reference":[{"key":"68570_CR1","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1146\/annurev-med-070909-182917","volume":"62","author":"CK Osborne","year":"2011","unstructured":"Osborne, C. K. & Schiff, R. Mechanisms of endocrine resistance in breast cancer. Annu Rev. Med. 62, 233\u2013247 (2011).","journal-title":"Annu Rev. Med."},{"key":"68570_CR2","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1210\/endo.138.3.5002","volume":"138","author":"L Altucci","year":"1997","unstructured":"Altucci, L. et al. Estrogen induces early and timed activation of cyclin-dependent kinases 4, 5, and 6 and increases cyclin messenger ribonucleic acid expression in rat uterus. Endocrinology 138, 978\u2013984 (1997).","journal-title":"Endocrinology"},{"key":"68570_CR3","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1002\/(SICI)1098-2795(199704)46:4<450::AID-MRD2>3.0.CO;2-N","volume":"46","author":"D Geum","year":"1997","unstructured":"Geum, D., Sun, W., Paik, S. K., Lee, C. C. & Kim, K. Estrogen-induced cyclin D1 and D3 gene expressions during mouse uterine cell proliferation in vivo: differential induction mechanism of cyclin D1 and D3. Mol. Reprod. Dev. 46, 450\u2013458 (1997).","journal-title":"Mol. Reprod. Dev."},{"key":"68570_CR4","doi-asserted-by":"publisher","first-page":"3933","DOI":"10.1210\/endo.138.9.5436","volume":"138","author":"TK Said","year":"1997","unstructured":"Said, T. K., Conneely, O. M., Medina, D., O\u2019Malley, B. W. & Lydon, J. P. Progesterone, in addition to estrogen, induces cyclin D1 expression in the murine mammary epithelial cell, in vivo. Endocrinology 138, 3933\u20133939 (1997).","journal-title":"Endocrinology"},{"key":"68570_CR5","doi-asserted-by":"publisher","first-page":"2251","DOI":"10.1128\/MCB.19.3.2251","volume":"19","author":"W Tong","year":"1999","unstructured":"Tong, W. & Pollard, J. W. Progesterone inhibits estrogen-induced cyclin D1 and cdk4 nuclear translocation, cyclin E- and cyclin A-cdk2 kinase activation, and cell proliferation in uterine epithelial cells in mice. Mol. Cell. Biol. 19, 2251\u20132264 (1999).","journal-title":"Mol. Cell. Biol."},{"key":"68570_CR6","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1530\/ERC-10-0262","volume":"18","author":"C Thangavel","year":"2011","unstructured":"Thangavel, C. et al. Therapeutically activating RB: reestablishing cell cycle control in endocrine therapy-resistant breast cancer. Endocr. Relat. Cancer 18, 333\u2013345 (2011).","journal-title":"Endocr. Relat. Cancer"},{"key":"68570_CR7","doi-asserted-by":"publisher","DOI":"10.1186\/s13058-015-0661-5","volume":"18","author":"RS Finn","year":"2016","unstructured":"Finn, R. S., Aleshin, A. & Slamon, D. J. Targeting the cyclin-dependent kinases (CDK) 4\/6 in estrogen receptor-positive breast cancers. Breast Cancer Res. 18, 17 (2016).","journal-title":"Breast Cancer Res."},{"key":"68570_CR8","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1038\/358259a0","volume":"358","author":"SJ Weintraub","year":"1992","unstructured":"Weintraub, S. J., Prater, C. A. & Dean, D. C. Retinoblastoma protein switches the E2F site from positive to negative element. Nature 358, 259\u2013261 (1992).","journal-title":"Nature"},{"key":"68570_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/j.drup.2024.101103","volume":"76","author":"A Glaviano","year":"2024","unstructured":"Glaviano, A. et al. Mechanisms of sensitivity and resistance to CDK4\/CDK6 inhibitors in hormone receptor-positive breast cancer treatment. Drug Resist. Updat. 76, 101103 (2024).","journal-title":"Drug Resist. Updat."},{"key":"68570_CR10","doi-asserted-by":"publisher","first-page":"987","DOI":"10.3390\/diagnostics13050987","volume":"13","author":"I-M Stanciu","year":"2023","unstructured":"Stanciu, I.-M. et al. Mechanisms of resistance to CDK4\/6 inhibitors and predictive biomarkers of response in HR+\/HER2-metastatic breast cancer\u2014A review of the literature. Diagnostics 13, 987 (2023).","journal-title":"Diagnostics"},{"key":"68570_CR11","doi-asserted-by":"publisher","first-page":"4055","DOI":"10.1158\/1078-0432.CCR-16-3206","volume":"23","author":"CX Ma","year":"2017","unstructured":"Ma, C. X. et al. NeoPalAna: neoadjuvant palbociclib, a cyclin-dependent kinase 4\/6 inhibitor, and anastrozole for clinical stage 2 or 3 estrogen receptor-positive breast cancer. Clin. Cancer Res. 23, 4055\u20134065 (2017).","journal-title":"Clin. Cancer Res."},{"key":"68570_CR12","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-05914-x","volume":"9","author":"OL Griffith","year":"2018","unstructured":"Griffith, O. L. et al. The prognostic effects of somatic mutations in ER-positive breast cancer. Nat. Commun. 9, 3476 (2018).","journal-title":"Nat. Commun."},{"key":"68570_CR13","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1038\/nature11143","volume":"486","author":"MJ Ellis","year":"2012","unstructured":"Ellis, M. J. et al. Whole-genome analysis informs breast cancer response to aromatase inhibition. Nature 486, 353\u2013360 (2012).","journal-title":"Nature"},{"key":"68570_CR14","doi-asserted-by":"publisher","first-page":"8581","DOI":"10.1002\/cam4.4376","volume":"10","author":"I Grote","year":"2021","unstructured":"Grote, I. et al. TP53 mutations are associated with primary endocrine resistance in luminal early breast cancer. Cancer Med. 10, 8581\u20138594 (2021).","journal-title":"Cancer Med."},{"key":"68570_CR15","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1158\/1078-0432.CCR-18-4044","volume":"26","author":"A Pearson","year":"2020","unstructured":"Pearson, A. et al. Inactivating NF1 mutations are enriched in advanced breast cancer and contribute to endocrine therapy resistance. Clin. Cancer Res. 26, 608\u2013622 (2020).","journal-title":"Clin. Cancer Res."},{"key":"68570_CR16","doi-asserted-by":"publisher","DOI":"10.1186\/s13058-014-0430-x","volume":"16","author":"X Fu","year":"2014","unstructured":"Fu, X. et al. Overcoming endocrine resistance due to reduced PTEN levels in estrogen receptor-positive breast cancer by co-targeting mammalian target of rapamycin, protein kinase B, or mitogen-activated protein kinase kinase. Breast Cancer Res. 16, 430 (2014).","journal-title":"Breast Cancer Res."},{"key":"68570_CR17","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1038\/nature11412","volume":"490","author":"Cancer Genome Atlas Network","year":"2012","unstructured":"Cancer Genome Atlas Network Comprehensive molecular portraits of human breast tumours. Nature 490, 61\u201370 (2012).","journal-title":"Nature"},{"key":"68570_CR18","doi-asserted-by":"publisher","first-page":"53","DOI":"10.3390\/biom7030053","volume":"7","author":"Y Fallah","year":"2017","unstructured":"Fallah, Y., Brundage, J., Allegakoen, P. & Shajahan-Haq, A. N. MYC-driven pathways in breast cancer subtypes. Biomolecules 7, 53 (2017).","journal-title":"Biomolecules"},{"key":"68570_CR19","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1001\/jamaoncol.2023.6038","volume":"10","author":"CX Ma","year":"2024","unstructured":"Ma, C. X. et al. Endocrine-sensitive disease rate in postmenopausal patients with estrogen receptor-rich\/ERBB2-negative breast cancer receiving neoadjuvant anastrozole, fulvestrant, or their combination: a phase 3 randomized clinical trial. JAMA Oncol. 10, 362\u2013371 (2024).","journal-title":"JAMA Oncol."},{"key":"68570_CR20","doi-asserted-by":"publisher","first-page":"2158","DOI":"10.1158\/1535-7163.MCT-19-0162","volume":"18","author":"T Kong","year":"2019","unstructured":"Kong, T. et al. eIF4A inhibitors suppress cell-cycle feedback response and acquired resistance to CDK4\/6 inhibition in cancer. Mol. Cancer Ther. 18, 2158\u20132170 (2019).","journal-title":"Mol. Cancer Ther."},{"key":"68570_CR21","doi-asserted-by":"publisher","DOI":"10.1186\/s13058-020-01320-8","volume":"22","author":"NA O\u2019Brien","year":"2020","unstructured":"O\u2019Brien, N. A. et al. Targeting activated PI3K\/mTOR signaling overcomes acquired resistance to CDK4\/6-based therapies in preclinical models of hormone receptor-positive breast cancer. Breast Cancer Res. 22, 89 (2020).","journal-title":"Breast Cancer Res."},{"key":"68570_CR22","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1038\/nrd.2017.267","volume":"17","author":"DM Schwartz","year":"2017","unstructured":"Schwartz, D. M. et al. JAK inhibition as a therapeutic strategy for immune and inflammatory diseases. Nat. Rev. Drug Discov. 17, 78 (2017).","journal-title":"Nat. Rev. Drug Discov."},{"key":"68570_CR23","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1182\/blood-2017-04-742288","volume":"130","author":"P Bose","year":"2017","unstructured":"Bose, P. & Verstovsek, S. JAK2 inhibitors for myeloproliferative neoplasms: what is next? Blood 130, 115\u2013125 (2017).","journal-title":"Blood"},{"key":"68570_CR24","doi-asserted-by":"publisher","first-page":"e14","DOI":"10.1016\/S2352-3026(21)00367-7","volume":"9","author":"R Zeiser","year":"2022","unstructured":"Zeiser, R. et al. Efficacy and safety of itacitinib versus placebo in combination with corticosteroids for initial treatment of acute graft-versus-host disease (GRAVITAS-301): a randomised, multicentre, double-blind, phase 3 trial. Lancet Haematol. 9, e14\u2013e25 (2022).","journal-title":"Lancet Haematol."},{"key":"68570_CR25","doi-asserted-by":"publisher","first-page":"5121","DOI":"10.1158\/1078-0432.CCR-15-0360","volume":"21","author":"SE Wardell","year":"2015","unstructured":"Wardell, S. E. et al. Efficacy of SERD\/SERM Hybrid-CDK4\/6 inhibitor combinations in models of endocrine therapy-resistant breast cancer. Clin. Cancer Res. 21, 5121\u20135130 (2015).","journal-title":"Clin. Cancer Res."},{"key":"68570_CR26","doi-asserted-by":"publisher","first-page":"eaar3593","DOI":"10.1126\/science.aar3593","volume":"362","author":"R Cristescu","year":"2018","unstructured":"Cristescu, R. et al. Pan-tumor genomic biomarkers for PD-1 checkpoint blockade-based immunotherapy. Science 362, eaar3593 (2018).","journal-title":"Science"},{"key":"68570_CR27","doi-asserted-by":"publisher","DOI":"10.1038\/s41698-022-00297-1","volume":"6","author":"Z Zhu","year":"2022","unstructured":"Zhu, Z. et al. Comparative biomarker analysis of PALOMA-2\/3 trials for palbociclib. NPJ Precis Oncol. 6, 56 (2022).","journal-title":"NPJ Precis Oncol."},{"key":"68570_CR28","doi-asserted-by":"publisher","first-page":"2930","DOI":"10.1172\/JCI91190","volume":"127","author":"M Ayers","year":"2017","unstructured":"Ayers, M. et al. IFN-\u03b3-related mRNA profile predicts clinical response to PD-1 blockade. J. Clin. Invest. 127, 2930\u20132940 (2017).","journal-title":"J. Clin. Invest."},{"key":"68570_CR29","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1186\/s13045-018-0644-y","volume":"11","author":"M Liu","year":"2018","unstructured":"Liu, M. et al. Targeting the IDO1 pathway in cancer: from bench to bedside. J. Hematol. Oncol. 11, 100 (2018).","journal-title":"J. Hematol. Oncol."},{"key":"68570_CR30","doi-asserted-by":"publisher","first-page":"e074819","DOI":"10.1136\/bmj-2023-074819","volume":"384","author":"GS Collins","year":"2024","unstructured":"Collins, G. S. et al. Evaluation of clinical prediction models (part 1): from development to external validation. BMJ 384, e074819 (2024).","journal-title":"BMJ"},{"key":"68570_CR31","doi-asserted-by":"publisher","DOI":"10.1038\/s41698-023-00438-0","volume":"7","author":"AK Witkiewicz","year":"2023","unstructured":"Witkiewicz, A. K. et al. Determinants of response to CDK4\/6 inhibitors in the real-world setting. NPJ Precis Oncol. 7, 90 (2023).","journal-title":"NPJ Precis Oncol."},{"key":"68570_CR32","doi-asserted-by":"publisher","DOI":"10.1038\/s41523-023-00520-7","volume":"9","author":"A Grinshpun","year":"2023","unstructured":"Grinshpun, A., Tolaney, S. M., Burstein, H. J., Jeselsohn, R. & Mayer, E. L. The dilemma of selecting a first line CDK4\/6 inhibitor for hormone receptor-positive\/HER2-negative metastatic breast cancer. npj Breast Cancer 9, 15 (2023).","journal-title":"npj Breast Cancer"},{"key":"68570_CR33","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1038\/s41571-023-00840-4","volume":"21","author":"L Morrison","year":"2024","unstructured":"Morrison, L., Loibl, S. & Turner, N. C. The CDK4\/6 inhibitor revolution - a game-changing era for breast cancer treatment. Nat. Rev. Clin. Oncol. 21, 89\u2013105 (2024).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"68570_CR34","doi-asserted-by":"publisher","first-page":"3246","DOI":"10.1200\/JCO.22.00338","volume":"40","author":"FC Bidard","year":"2022","unstructured":"Bidard, F. C. et al. Elacestrant (oral selective estrogen receptor degrader) versus standard endocrine therapy for estrogen receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: results from the randomized phase III EMERALD trial. J. Clin. Oncol. 40, 3246\u20133256 (2022).","journal-title":"J. Clin. Oncol."},{"key":"68570_CR35","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1016\/S1470-2045(21)00034-6","volume":"22","author":"HS Rugo","year":"2021","unstructured":"Rugo, H. S. et al. Alpelisib plus fulvestrant in PIK3CA-mutated, hormone receptor-positive advanced breast cancer after a CDK4\/6 inhibitor (BYLieve): one cohort of a phase 2, multicentre, open-label, non-comparative study. Lancet Oncol. 22, 489\u2013498 (2021).","journal-title":"Lancet Oncol."},{"key":"68570_CR36","doi-asserted-by":"publisher","first-page":"2058","DOI":"10.1056\/NEJMoa2214131","volume":"388","author":"NC Turner","year":"2023","unstructured":"Turner, N. C. et al. Capivasertib in hormone receptor-positive advanced breast cancer. N. Engl. J. Med. 388, 2058\u20132070 (2023).","journal-title":"N. Engl. J. Med."},{"key":"68570_CR37","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.1038\/s41388-024-02986-6","volume":"43","author":"A Vasseur","year":"2024","unstructured":"Vasseur, A. et al. Fulvestrant and everolimus efficacy after CDK4\/6 inhibitor: a prospective study with circulating tumor DNA analysis. Oncogene 43, 1214\u20131222 (2024).","journal-title":"Oncogene"},{"key":"68570_CR38","volume":"13","author":"R Palumbo","year":"2024","unstructured":"Palumbo, R. et al. Efficacy and activity of treatments after progression from palbociclib plus endocrine therapy in patients with HR(+)\/HER2(-) metastatic breast cancer: a prospective, monocentric study. Drugs Context 13, 2023-7-5 (2024).","journal-title":"Drugs Context"},{"key":"68570_CR39","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.1200\/JCO.18.00925","volume":"37","author":"NC Turner","year":"2019","unstructured":"Turner, N. C. et al. Cyclin E1 expression and palbociclib efficacy in previously treated hormone receptor\u2013positive metastatic breast cancer. J. Clin. Oncol. 37, 1169\u20131178 (2019).","journal-title":"J. Clin. Oncol."},{"key":"68570_CR40","doi-asserted-by":"publisher","first-page":"1557","DOI":"10.1158\/1078-0432.CCR-22-2206","volume":"29","author":"\u00c1 Guerrero-Zotano","year":"2023","unstructured":"Guerrero-Zotano, \u00c1 et al. CCNE1 and PLK1 mediate resistance to palbociclib in HR+\/HER2- metastatic breast cancer. Clin. Cancer Res. 29, 1557\u20131568 (2023).","journal-title":"Clin. Cancer Res."},{"key":"68570_CR41","doi-asserted-by":"publisher","first-page":"1404","DOI":"10.1016\/j.ccell.2021.08.009","volume":"39","author":"K Freeman-Cook","year":"2021","unstructured":"Freeman-Cook, K. et al. Expanding control of the tumor cell cycle with a CDK2\/4\/6 inhibitor. Cancer Cell 39, 1404\u20131421.e1411 (2021).","journal-title":"Cancer Cell"},{"key":"68570_CR42","doi-asserted-by":"publisher","DOI":"10.1038\/s41523-018-0092-4","volume":"4","author":"C Guarducci","year":"2018","unstructured":"Guarducci, C. et al. Cyclin E1 and Rb modulation as common events at time of resistance to palbociclib in hormone receptor-positive breast cancer. NPJ Breast Cancer 4, 38 (2018).","journal-title":"NPJ Breast Cancer"},{"key":"68570_CR43","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-45796-w","volume":"15","author":"J Ma","year":"2024","unstructured":"Ma, J. et al. MYC induces CDK4\/6 inhibitors resistance by promoting pRB1 degradation. Nat. Commun. 15, 1871 (2024).","journal-title":"Nat. Commun."},{"key":"68570_CR44","doi-asserted-by":"publisher","first-page":"9282","DOI":"10.1073\/pnas.1807155115","volume":"115","author":"R Sonntag","year":"2018","unstructured":"Sonntag, R. et al. Cyclin E1 and cyclin-dependent kinase 2 are critical for initiation, but not for progression of hepatocellular carcinoma. Proc. Natl. Acad. Sci. USA 115, 9282\u20139287 (2018).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"68570_CR45","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1158\/2159-8290.CD-23-0954","volume":"14","author":"C Dietrich","year":"2024","unstructured":"Dietrich, C. et al. INX-315, a selective CDK2 inhibitor, induces cell cycle arrest and senescence in solid tumors. Cancer Discov. 14, 446\u2013467 (2024).","journal-title":"Cancer Discov."},{"key":"68570_CR46","doi-asserted-by":"publisher","first-page":"1889","DOI":"10.1158\/1078-0432.CCR-23-2975","volume":"30","author":"C Guarducci","year":"2024","unstructured":"Guarducci, C. et al. Selective CDK7 inhibition suppresses cell cycle progression and MYC signaling while enhancing apoptosis in therapy-resistant estrogen receptor-positive breast cancer. Clin. Cancer Res. 30, 1889\u20131905 (2024).","journal-title":"Clin. Cancer Res."},{"key":"68570_CR47","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2318093121","volume":"121","author":"R Cencic","year":"2024","unstructured":"Cencic, R. et al. A second-generation eIF4A RNA helicase inhibitor exploits translational reprogramming as a vulnerability in triple-negative breast cancer. Proc. Natl. Acad. Sci. USA 121, e2318093121 (2024).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"68570_CR48","doi-asserted-by":"crossref","unstructured":"Chen, A. et al. PKMYT1 is a marker of treatment response and a therapeutic target for CDK4\/6 inhibitor-resistance in ER+ breast cancer. Mol. Cancer Ther. 23, 1494\u20131510 (2024).","DOI":"10.1158\/1535-7163.MCT-23-0564"},{"key":"68570_CR49","doi-asserted-by":"publisher","first-page":"1174","DOI":"10.1158\/2159-8290.CD-19-1390","volume":"10","author":"SA Wander","year":"2020","unstructured":"Wander, S. A. et al. The genomic landscape of intrinsic and acquired resistance to cyclin-dependent kinase 4\/6 inhibitors in patients with hormone receptor\u2013positive metastatic breast cancer. Cancer Discov. 10, 1174\u20131193 (2020).","journal-title":"Cancer Discov."},{"key":"68570_CR50","doi-asserted-by":"publisher","first-page":"107504","DOI":"10.1016\/j.celrep.2020.03.068","volume":"31","author":"J Romero-Pozuelo","year":"2020","unstructured":"Romero-Pozuelo, J., Figlia, G., Kaya, O., Martin-Villalba, A. & Teleman, A. A. Cdk4 and Cdk6 couple the cell-cycle machinery to cell growth via mTORC1. Cell Rep. 31, 107504 (2020).","journal-title":"Cell Rep."},{"key":"68570_CR51","doi-asserted-by":"publisher","first-page":"11354","DOI":"10.1158\/0008-5472.CAN-05-2236","volume":"65","author":"SJ Zacharek","year":"2005","unstructured":"Zacharek, S. J., Xiong, Y. & Shumway, S. D. Negative regulation of TSC1-TSC2 by mammalian D-type cyclins. Cancer Res. 65, 11354\u201311360 (2005).","journal-title":"Cancer Res."},{"key":"68570_CR52","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1158\/1535-7163.MCT-17-0537","volume":"17","author":"C Michaloglou","year":"2018","unstructured":"Michaloglou, C. et al. Combined inhibition of mTOR and CDK4\/6 is required for optimal blockade of E2F function and long-term growth inhibition in estrogen receptor-positive breast cancer. Mol. Cancer Ther. 17, 908\u2013920 (2018).","journal-title":"Mol. Cancer Ther."},{"key":"68570_CR53","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-023-29425-y","volume":"13","author":"MJ Rodriguez","year":"2023","unstructured":"Rodriguez, M. J. et al. Targeting mTOR to overcome resistance to hormone and CDK4\/6 inhibitors in ER-positive breast cancer models. Sci. Rep. 13, 2710 (2023).","journal-title":"Sci. Rep."},{"key":"68570_CR54","doi-asserted-by":"publisher","first-page":"77","DOI":"10.12659\/MSM.912929","volume":"25","author":"L Chen","year":"2019","unstructured":"Chen, L., Yang, G. & Dong, H. Everolimus reverses palbociclib resistance in ER+ Human breast cancer cells by inhibiting phosphatidylinositol 3-kinase(PI3K)\/Akt\/mammalian target of rapamycin (mTOR) pathway. Med. Sci. Monit. 25, 77\u201386 (2019).","journal-title":"Med. Sci. Monit."},{"key":"68570_CR55","doi-asserted-by":"publisher","first-page":"1584","DOI":"10.1056\/NEJMoa2404625","volume":"391","author":"NC Turner","year":"2024","unstructured":"Turner, N. C. et al. Inavolisib-based therapy in PIK3CA-mutated advanced breast cancer. N. Engl. J. Med. 391, 1584\u20131596 (2024).","journal-title":"N. Engl. J. Med."},{"key":"68570_CR56","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-55643-7","volume":"16","author":"T Kong","year":"2025","unstructured":"Kong, T. et al. RSK1 is an exploitable dependency in myeloproliferative neoplasms and secondary acute myeloid leukemia. Nat. Commun. 16, 492 (2025).","journal-title":"Nat. Commun."},{"key":"68570_CR57","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1158\/1078-0432.CCR-19-0751","volume":"26","author":"RS Finn","year":"2020","unstructured":"Finn, R. S. et al. Biomarker analyses of response to cyclin-dependent kinase 4\/6 inhibition and endocrine therapy in women with treatment-na\u00efve metastatic breast cancer. Clin. Cancer Res. 26, 110\u2013121 (2020).","journal-title":"Clin. Cancer Res."},{"key":"68570_CR58","doi-asserted-by":"publisher","DOI":"10.1038\/s41523-024-00658-y","volume":"10","author":"MCU Cheang","year":"2024","unstructured":"Cheang, M. C. U. et al. Effect of cross-platform gene-expression, computational methods on breast cancer subtyping in PALOMA-2 and PALLET studies. NPJ Breast Cancer 10, 54 (2024).","journal-title":"NPJ Breast Cancer"},{"key":"68570_CR59","doi-asserted-by":"publisher","first-page":"1458","DOI":"10.1200\/JCO.20.02977","volume":"39","author":"A Prat","year":"2021","unstructured":"Prat, A. et al. Correlative biomarker analysis of intrinsic subtypes and efficacy across the MONALEESA phase III studies. J. Clin. Oncol. 39, 1458\u20131467 (2021).","journal-title":"J. Clin. Oncol."},{"key":"68570_CR60","doi-asserted-by":"publisher","first-page":"4870","DOI":"10.1158\/1078-0432.CCR-19-4191","volume":"27","author":"C De Angelis","year":"2021","unstructured":"De Angelis, C. et al. Activation of the IFN signaling pathway is associated with resistance to CDK4\/6 inhibitors and immune checkpoint activation in ER-positive breast cancer. Clin. Cancer Res. 27, 4870\u20134882 (2021).","journal-title":"Clin. Cancer Res."},{"key":"68570_CR61","doi-asserted-by":"publisher","first-page":"3996","DOI":"10.1158\/1078-0432.CCR-18-3274","volume":"25","author":"NM Kettner","year":"2019","unstructured":"Kettner, N. M. et al. Combined inhibition of STAT3 and DNA Repair In Palbociclib-resistant ER-Positive Breast Cancer. Clin. Cancer Res 25, 3996\u20134013 (2019).","journal-title":"Clin. Cancer Res"},{"key":"68570_CR62","doi-asserted-by":"crossref","unstructured":"Tsimberidou, A. M. et al. Phase 1 trial of TTI\u2212101, a first-in-class oral inhibitor of STAT3 in patients with advanced solid tumors. Clin. Cancer Res. 31, 965\u2013974 (2025).","DOI":"10.1158\/1078-0432.CCR-24-2920"},{"key":"68570_CR63","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1186\/s13045-016-0367-x","volume":"9","author":"S Verstovsek","year":"2016","unstructured":"Verstovsek, S. et al. Phase 1\/2 study of pacritinib, a next generation JAK2\/FLT3 inhibitor, in myelofibrosis or other myeloid malignancies. J. Hematol. Oncol. 9, 137 (2016).","journal-title":"J. Hematol. Oncol."},{"key":"68570_CR64","doi-asserted-by":"publisher","first-page":"e1008824","DOI":"10.1080\/2162402X.2015.1008824","volume":"4","author":"R Bellucci","year":"2015","unstructured":"Bellucci, R. et al. Interferon-\u03b3-induced activation of JAK1 and JAK2 suppresses tumor cell susceptibility to NK cells through upregulation of PD-L1 expression. Oncoimmunology 4, e1008824 (2015).","journal-title":"Oncoimmunology"},{"key":"68570_CR65","doi-asserted-by":"publisher","first-page":"200ra116","DOI":"10.1126\/scitranslmed.3006504","volume":"5","author":"S Spranger","year":"2013","unstructured":"Spranger, S. et al. Up-regulation of PD-L1, IDO, and T(regs) in the melanoma tumor microenvironment is driven by CD8(+) T cells. Sci. Transl. Med. 5, 200ra116 (2013).","journal-title":"Sci. Transl. Med."},{"key":"68570_CR66","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1093\/jnci\/djz213","volume":"112","author":"M Anurag","year":"2019","unstructured":"Anurag, M. et al. Immune checkpoint profiles in luminal B breast cancer (Alliance). JNCI: J. Natl. Cancer Inst. 112, 737\u2013746 (2019).","journal-title":"JNCI: J. Natl. Cancer Inst."},{"key":"68570_CR67","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1200\/JCO.2016.69.4406","volume":"35","author":"MJ Ellis","year":"2017","unstructured":"Ellis, M. J. et al. Ki67 proliferation index as a tool for chemotherapy decisions during and after neoadjuvant aromatase inhibitor treatment of breast cancer: results from the American College of Surgeons Oncology Group Z1031 trial (Alliance). J. Clin. Oncol. 35, 1061\u20131069 (2017).","journal-title":"J. Clin. Oncol."},{"key":"68570_CR68","doi-asserted-by":"publisher","unstructured":"Patel, P. G. et al. Preparation of formalin-fixed paraffin-embedded tissue cores for both RNA and DNA extraction. J. Vis. Exp. 54299 https:\/\/doi.org\/10.3791\/54299 (2016).","DOI":"10.3791\/54299"},{"key":"68570_CR69","first-page":"108","volume":"4","author":"T Kong","year":"2023","unstructured":"Kong, T. et al. DUSP6 mediates resistance to JAK2 inhibition and drives leukemic progression. Nat. Cancer 4, 108\u2013127 (2023).","journal-title":"Nat. Cancer"},{"key":"68570_CR70","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-014-0550-8","volume":"15","author":"MI Love","year":"2014","unstructured":"Love, M. I., Huber, W. & Anders, S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 15, 550 (2014).","journal-title":"Genome Biol."},{"key":"68570_CR71","doi-asserted-by":"publisher","first-page":"15545","DOI":"10.1073\/pnas.0506580102","volume":"102","author":"A Subramanian","year":"2005","unstructured":"Subramanian, A. et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl. Acad. Sci. USA 102, 15545\u201315550 (2005).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"68570_CR72","doi-asserted-by":"crossref","unstructured":"Rajput, S. et al. Inhibition of cyclin dependent kinase 9 by dinaciclib suppresses cyclin B1 expression and tumor growth in triple negative breast cancer. Oncotarget 7, 56864\u201356875 (2016).","DOI":"10.18632\/oncotarget.10870"},{"key":"68570_CR73","doi-asserted-by":"publisher","first-page":"3857","DOI":"10.3390\/cancers12123857","volume":"12","author":"Z Guo","year":"2020","unstructured":"Guo, Z. et al. Proteomic resistance biomarkers for PI3K inhibitor in triple negative breast cancer patient-derived xenograft models. Cancers 12, 3857 (2020).","journal-title":"Cancers"},{"key":"68570_CR74","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1038\/s41592-018-0051-x","volume":"15","author":"S Kim","year":"2018","unstructured":"Kim, S. et al. Strelka2: fast and accurate calling of germline and somatic variants. Nat. Methods 15, 591\u2013594 (2018).","journal-title":"Nat. Methods"},{"key":"68570_CR75","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1038\/nbt.2514","volume":"31","author":"K Cibulskis","year":"2013","unstructured":"Cibulskis, K. et al. Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples. Nat. Biotechnol. 31, 213\u2013219 (2013).","journal-title":"Nat. Biotechnol."},{"key":"68570_CR76","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1101\/gr.129684.111","volume":"22","author":"DC Koboldt","year":"2012","unstructured":"Koboldt, D. C. et al. VarScan 2: somatic mutation and copy number alteration discovery in cancer by exome sequencing. Genome Res. 22, 568\u2013576 (2012).","journal-title":"Genome Res."},{"key":"68570_CR77","doi-asserted-by":"publisher","first-page":"2865","DOI":"10.1093\/bioinformatics\/btp394","volume":"25","author":"K Ye","year":"2009","unstructured":"Ye, K., Schulz, M. H., Long, Q., Apweiler, R. & Ning, Z. Pindel: a pattern growth approach to detect break points of large deletions and medium sized insertions from paired-end short reads. Bioinformatics 25, 2865\u20132871 (2009).","journal-title":"Bioinformatics"},{"key":"68570_CR78","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-14381-2","volume":"11","author":"S Satpathy","year":"2020","unstructured":"Satpathy, S. et al. Microscaled proteogenomic methods for precision oncology. Nat. Commun. 11, 532 (2020).","journal-title":"Nat. Commun."},{"key":"68570_CR79","doi-asserted-by":"crossref","unstructured":"Li, S. et al. Neratinib synergizes with trastuzumab antibody drug conjugate or with vinorelbine to treat HER2 mutated breast cancer patient derived xenografts and organoids. Preprint at https:\/\/www.biorxiv.org\/content\/10.1101\/2023.12.19.572069v1 (2023).","DOI":"10.1101\/2023.12.19.572069"},{"key":"68570_CR80","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1016\/j.gpb.2022.01.004","volume":"20","author":"S Zheng","year":"2022","unstructured":"Zheng, S. et al. SynergyFinder plus: toward better interpretation and annotation of drug combination screening datasets. Genom. Proteom. Bioinforma. 20, 587\u2013596 (2022).","journal-title":"Genom. Proteom. Bioinforma."},{"key":"68570_CR81","doi-asserted-by":"publisher","first-page":"e20212062","DOI":"10.1084\/jem.20212062","volume":"220","author":"C Zuo","year":"2023","unstructured":"Zuo, C. et al. Stromal and therapy-induced macrophage proliferation promotes PDAC progression and susceptibility to innate immunotherapy. J. Exp. Med. 220, e20212062 (2023).","journal-title":"J. Exp. Med."},{"key":"68570_CR82","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1038\/nature10983","volume":"486","author":"C Curtis","year":"2012","unstructured":"Curtis, C. et al. The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature 486, 346\u2013352 (2012).","journal-title":"Nature"},{"key":"68570_CR83","doi-asserted-by":"publisher","first-page":"e078378","DOI":"10.1136\/bmj-2023-078378","volume":"385","author":"GS Collins","year":"2024","unstructured":"Collins, G. S. et al. TRIPOD+AI statement: updated guidance for reporting clinical prediction models that use regression or machine learning methods. BMJ 385, e078378 (2024).","journal-title":"BMJ"}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-68570-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-68570-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-68570-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T10:02:30Z","timestamp":1769508150000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-68570-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,27]]},"references-count":83,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["68570"],"URL":"https:\/\/doi.org\/10.1038\/s41467-026-68570-6","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,27]]},"assertion":[{"value":"17 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"C.X.M. received research funding from Pfizer Pharmaceuticals. C.X.M. received advisory\/consulting fees from Eli Lilly, Stemline, Novartis, TerSera Therapeutics, AstraZeneca, Olaris, Pfizer, Stemline, Daiichi, Merck, Regor Therapeutics, Danatlas. I.S.H. received advisory board fees from AstraZeneca. The remaining authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"949"}}